1                         When combined with a serum LDH > 1500 IU/L, this is the most powerful poor pr

2                                     Baseline serum LDH level was moderately accurate for predicting p

3   A significant interaction between baseline serum LDH and treatment was observed; oblimersen signifi

4 at 18 months (AUC = 0.813) than did baseline serum LDH levels alone for prediction of progression-fre

5 val in patients without an elevated baseline serum LDH.

6    In multivariate analysis, a high baseline serum LDH level was associated with decreased progressio

7                  The combination of baseline serum LDH levels and evaluation with MASS criteria at th

8                    A combination of baseline serum LDH levels and evaluation with MASS criteria at th

9 ncreased survival in patients whose baseline serum LDH was not elevated (median overall survival, 11.

10 overall or event-free survival, whereas both serum LDH and stage influenced both overall and event-fr

11                                     Elevated serum LDH or higher modified stage were associated with

12                                  An elevated serum LDH concentration or a chest radiograph with granu

13 DH >two-thirds the upper limit of normal for serum LDH) were absent (LR, 0.04; 95% CI, 0.02-0.11).

14                                         High serum LDH levels are associated with poor prognosis in p

15  PFS in patients (n = 158 per arm) with high serum LDH, a potential marker of hypoxia, PFS was longer

16     FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities.

17 ion of baseline clinical variables including serum LDH and imaging findings with progression-free and

18                         We hypothesized that serum LDH may represent a convenient biomarker of intrav

19 rotein >0.5, a ratio of pleural fluid LDH to serum LDH >0.6, or pleural fluid LDH >two-thirds the upp

20                            We tested whether serum LDH is prognostic and has predictive value in pati